Curis | CRIS - Cash And Equivalent


Curis reported $10.14M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Alaunos Therapeutics USD 1.94M 941K Sep/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bayer EUR 5.9B 1.34B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
CSL USD 2.16B 633M Jun/2025
Curis USD 10.14M 10.14M Jun/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Exelixis USD 482.49M 106.19M Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Takeda JPY 654.94B 26.55B Dec/2025
TG Therapeutics USD 199.51M 21.2M Dec/2025
Verastem USD 137.71M 20.14M Sep/2025
Xoma USD 143.9M 7.68M Jun/2024